ÖZCAN, M. Et Al. 2021. Copanlisib plus rituximab vs placebo plus rituximab in patients (pts) with relapsed marginal zone lymphoma (MZL) treated in the Phase III CHRONOS-3 trial. ESMO 2021 .

ÖZCAN, M., JİN, J., Szomor, Á., Panayiotis, P., Yoon, D. H., Tyczyńska, A., ... Soler, L. M.(2021). Copanlisib plus rituximab vs placebo plus rituximab in patients (pts) with relapsed marginal zone lymphoma (MZL) treated in the Phase III CHRONOS-3 trial . ESMO 2021

ÖZCAN, MUHİT Et Al. "Copanlisib plus rituximab vs placebo plus rituximab in patients (pts) with relapsed marginal zone lymphoma (MZL) treated in the Phase III CHRONOS-3 trial," ESMO 2021, 2021

ÖZCAN, MUHİT Et Al. "Copanlisib plus rituximab vs placebo plus rituximab in patients (pts) with relapsed marginal zone lymphoma (MZL) treated in the Phase III CHRONOS-3 trial." ESMO 2021 , 2021

ÖZCAN, M. Et Al. (2021) . "Copanlisib plus rituximab vs placebo plus rituximab in patients (pts) with relapsed marginal zone lymphoma (MZL) treated in the Phase III CHRONOS-3 trial." ESMO 2021 .

@conferencepaper{conferencepaper, author={MUHİT ÖZCAN Et Al. }, title={Copanlisib plus rituximab vs placebo plus rituximab in patients (pts) with relapsed marginal zone lymphoma (MZL) treated in the Phase III CHRONOS-3 trial}, congress name={ESMO 2021}, city={}, country={}, year={2021}}